Triptan overuse during pregnancy: a possible cause of placental hypoperfusion

Eur J Clin Pharmacol. 2021 Feb;77(2):269-270. doi: 10.1007/s00228-020-02991-0. Epub 2020 Sep 4.

Authors

Delphine Viard¹, Alexandre Gérard², Jellila Tahiri³, Nathalie Tieulié⁴, Elise Van Obberghen², Milou-Daniel Drici²

Affiliations

¹ Department of Pharmacology, Pharmacovigilance Center, University Hospital of Nice, Nice, France. viard.d@chu-nice.fr.
² Department of Pharmacology, Pharmacovigilance Center, University Hospital of Nice, Nice, France.
³ Department of Obstetrics and Gynecology, University Hospital of Nice, Nice, France.
⁴ Department of Rheumatology, University Hospital of Nice, Nice, France.

PMID: 32886179
DOI: 10.1007/s00228-020-02991-0

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Adult
Cesarean Section
Female
Humans
Infant, Newborn
Live Birth
Male
Migraine with Aura / drug therapy*
Placenta / blood supply*
Placental Circulation / drug effects*
Pregnancy
Pregnancy Complications / chemically induced*
Pregnancy Complications / diagnostic imaging
Pregnancy Complications / physiopathology
Premature Birth
Risk Factors
Serotonin Receptor Agonists / adverse effects*
Tryptamines / adverse effects*

Substances

Serotonin Receptor Agonists
Tryptamines
almotriptan